From GE Healthcare;
GE Healthcare has added the Signa HDe 1.5T™, a compact MRI device at an affordable price to its family of MRI products. It has a single electronic cabinet that can be positioned inside the scanner room rather than in a separate equipment room. The Signa HDe 1.5T can be installed in the same physical location as 0.5T MRI systems with minimal construction costs. According to GE, the installation has been simplified to last only 7 days and has a 30 percent smaller footprint than a typical 1.5T system.
The 1.5T Signa™ HDe MRI system is substantially equivalent to the currently marketed GE 1.5T machines. The data acquisition system supports 1, 4, 8 independent receive channels and multiple independent coil elements per channel during a single acquisition series. The gradient specifications of HDe are lower than other GE Signa 1.5T MRI systems, but it can support clinical applications in cardiac and spectroscopy imaging.

Special imaging primarily means advanced MRI techniques used for qualitative and quantitative measurement of biological metabolism as e.g., spectroscopy, perfusion imaging (PWI, ASL), diffusion weighted imaging (DWI, DTI, DTT) and brain function (BOLD, fMRI). This physiological magnetic resonance techniques offer insights into brain structure, function, and metabolism.
Spectroscopy provides functional information related to identification and quantification of e.g. brain metabolites. MR perfusion imaging has applications in stroke, trauma, and brain neoplasm. MRI provides the high spatial and temporal resolution needed to measure blood flow to the brain. arterial spin labeling techniques utilize the intrinsic protons of blood and brain tissue, labeled by special preparation pulses, rather than exogenous tracers injected into the blood.
MR diffusion tensor imaging characterizes the ability of water to spread across the brain in different directions. Diffusion parallel to nerve fibers has been shown to be greater than diffusion in the perpendicular direction. This provides a tool to study in vivo fiber connectivity in brain MRI.
FMRI allows the detection of a functional activation in the brain because cortical activity is intimately related to local metabolism changes.

See also Diffusion Tensor Tractography.

The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents:

General MRI of the abdomen can consist of T1 or T2 weighted spin echo, fast spin echo (FSE, TSE) or gradient echo sequences with fat suppression and contrast enhanced MRI techniques. The examined organs include liver, pancreas, spleen, kidneys, adrenals as well as parts of the stomach and intestine (see also gastrointestinal imaging). Respiratory compensation and breath hold imaging is mandatory for a good image quality.
T1 weighted sequences are more sensitive for lesion detection than T2 weighted sequences at 0.5 T, while higher field strengths (greater than 1.0 T), T2 weighted and spoiled gradient echo sequences are used for focal lesion detection. Gradient echo in phase T1 breath hold can be performed as a dynamic series with the ability to visualize the blood distribution. Phases of contrast enhancement include the capillary or arterial dominant phase for demonstrating hypervascular lesions, in liver imaging the portal venous phase demonstrates the maximum difference between the liver and hypovascular lesions, while the equilibrium phase demonstrates interstitial disbursement for edematous and malignant tissues.
Out of phase gradient echo imaging for the abdomen is a lipid-type tissue sensitive sequence and is useful for the visualization of focal hepatic lesions, fatty liver (see also Dixon), hemochromatosis, adrenal lesions and renal masses. The standards for abdominal MRI vary according to clinical sites based on sequence availability and MRI equipment. Specific abdominal imaging coils and liver-specific contrast agents targeted to the healthy liver tissue improve the detection and localization of lesions.
See also Hepatobiliary Contrast Agents, Reticuloendothelial Contrast Agents, and Oral Contrast Agents.

For Ultrasound Imaging (USI) see Abdominal Ultrasound at Medical-Ultrasound-Imaging.com.

Breath hold imaging in MRI is a technique with one ore more stoppage of breathing during the sequence and require therefore a short scan time. Breath hold techniques are used with fast gradient echo sequences in thoracic or abdominal regions with much respiratory movement.
Breath hold cine MRI techniques are used in cardiovascular imaging and provide detailed views of the beating heart in different cardiac axes.
Breath hold imaging requires the full cooperation of the patient, caused by usual MRI scan times from 15 to 20 sec.. In some cases breath holding can be practiced outside the MRI scanner to improve patient cooperation with the examination. Shorter scan times e.g. by parallel imaging techniques, or the administration of oxygen can help the patient to hold the breath during the scan.
See also Abdominal Imaging.